Skip to main content

Amgen to Use BioWisdom's Sofia Software

NEW YORK (GenomeWeb News) – Pharmaceutical company Amgen has signed a multi-year license agreement to use BioWisdom’s knowledge network software, BioWisdom said today.
 
BioWisdom’s Sofia software is used to format large amounts of complex data that drug developers generate in their research. The Cambridge, UK-based firm said the software creates “Intelligence Networks, a unique format of assertional metadata that liberates knowledge from structured and unstructured data, regardless of its original format.”
 
Financial terms of the agreement were not released.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.